A recent study reveals that individuals who come off new weight-loss injections like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who end traditional diet and exercise regimens.
Published data in a prominent medical journal shows that while overweight people often shed substantial amounts of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"People buying such treatments should be aware of the potential of quick weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a reversion to original weight in about 18 months.
Analyzing Therapies
The research, which examined 37 of studies involving over 9,000 of patients, contrasted the effects of these new drugs with older methods.
Scientists emphasize that people who lose weight through dieting typically see a slower creep back—around 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts propose the mechanism of the drugs explains the accelerated weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations far above than normal may cause the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in appetite is no longer kept in check, making overeating much more probable."
A Chronic Condition?
The NHS recommend the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts say that, due to the high risk of weight regain, the therapy should be considered life-long.
This perspective is reinforced by drug manufacturers, who say that the results "underscore the persistent character of obesity," comparing it to managing conditions like diabetes.
User Testimonies
Individuals who have come off the jabs describe a intense resurgence of cravings.
"I experienced a trigger that goes on and you're instantly ravenous," described an individual.
This challenge is exacerbated if users have not established sustainable dietary or behavioural changes during therapy.
Significant Adoption
Survey data show that a significant number of adults in the UK have used these injections in the past year, with demand remaining high.
- Adoption is more common among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, experts stress that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and maintained weight loss likely depends on ongoing lifestyle changes.
